Quoin Pharmaceuticals (QNRX) Q2 2026 earnings summary

Executive summary

• Focused on developing therapies for rare and orphan diseases, with QRX003 as the lead candidate for Netherton Syndrome, now in pivotal registrational clinical testing in the US and internationally.

• Achieved FDA conditional approval for QYLEKI as the brand name for QRX003 targeting Netherton Syndrome.

• No products have been commercialized and no revenue generated to date; operations are funded by equity and debt financings.

• Recent regulatory milestones include FDA Fast Track, Japanese Orphan Drug Designation for QRX003, and IND clearance for Peeling Skin Syndrome.

• Advanced QRX009 topical rapamycin platform toward clinical testing in multiple rare dermatologic indications.

Financial highlights

• Net loss for Q2 2026 was $5.4 million, compared to $3.7 million in Q2 2025; net loss for the six months ended June 30, 2026 was $10.4 million, up from $7.5 million year-over-year.

• Operating expenses for Q2 2026 were $5.5 million, up from $3.8 million in Q2 2025, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $10.8 million as of June 30, 2026.

• Accumulated deficit reached $81.3 million as of June 30, 2026.

• Weighted average ADSs outstanding for Q2 2026: 2,832,915.

Outlook and guidance

• Management has concluded there is substantial doubt about the ability to continue as a going concern for at least one year without additional funding.

• Current cash position expected to fund operations into 2027.

• No revenue expected until successful development and marketing approval of product candidates, which is subject to significant uncertainty and expected to take years.

• Plans to seek further funding through equity, debt, or strategic partnerships.

• Phase 2/3 study for Peeling Skin Syndrome to enroll pediatric and adult patients in the US and Europe, initiating in 2H 2026.